---
title: "Corbus Pharma | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295106661.md"
datetime: "2026-08-06T12:17:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295106661.md)
  - [en](https://longbridge.com/en/news/295106661.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295106661.md)
generator: "portal-rs"
---

# Corbus Pharma | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -1.81, missing the estimate of USD -1.2611.

EBIT: As of FY2026 Q2, the actual value is USD -35.04 M.

#### Net Loss

Corbus Pharmaceuticals Holdings, Inc. reported a net loss of - $35.0 million for the three months ended June 30, 2026, compared to - $17.7 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $58.0 million, an increase from - $34.6 million for the six months ended June 30, 2025. 

#### Total Operating Expenses

Total operating expenses increased by $17.0 million to $36.2 million for the three months ended June 30, 2026, from $19.2 million for the same period in 2025. This increase was primarily due to higher clinical development expenses, including a $10.0 million development milestone payment related to the CRB-701 licensing agreement. 

#### Operating Loss

The company recorded an operating loss of - $36.2 million for the three months ended June 30, 2026, compared to an operating loss of - $19.2 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the operating loss was - $60.5 million, compared to - $38.9 million for the six months ended June 30, 2025. 

#### Cash, Cash Equivalents, and Investments

As of June 30, 2026, Corbus Pharmaceuticals Holdings, Inc. held $117.9 million in cash, cash equivalents, and investments. 

#### Cash Runway

Based on current operating plans and planned expenditures, Corbus Pharmaceuticals Holdings, Inc. expects its cash, cash equivalents, and investments to fund operations into 2028. 

#### Key Operational Updates

Corbus Pharmaceuticals Holdings, Inc. obtained FDA clearance for the TEMPO-1 registrational study of CRB-701 in 2L oropharyngeal cancer and concluded the last patient last visit in the CANYON-1 Phase 1b study of CRB-913 in obesity. The company also strengthened its senior leadership team with the appointment of a new Chief Medical Officer, Chief Business Officer, and Board Member. 

#### Outlook and Guidance

Corbus Pharmaceuticals Holdings, Inc. expects to initiate enrollment in the TEMPO-1 study for CRB-701 in September 2026 and is on track to report topline data from the CANYON-1 Phase 1b study for CRB-913 in September 2026. The company anticipates reporting CRB-701 + Keytruda® combination data in Q1 2027 to support potential registration-enabling trials in first-line oropharyngeal cancer patients.

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)

## Related News & Research

- [Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/299048598.md)
- [CRBP: CRB-701 and CRB-913 show promising efficacy and safety, advancing to pivotal studies](https://longbridge.com/en/news/298908736.md)
- [Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'](https://longbridge.com/en/news/298937370.md)
- [Corbus says Phase 1b CANYON-1 trial shows CRB-913 delivers 5% mean weight loss at 12 weeks in obesity study](https://longbridge.com/en/news/298907644.md)
- [Michael Saylor Says, 'A Little More Orange': Will Strategy Report BTC Purchases After Hitting Pause for 3 Weeks?](https://longbridge.com/en/news/299601303.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**